3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Squamous Cell Carcinoma of Head and Neck
7
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Adenocarcinoma Of Esophagus
3
Stomach Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Squamous Cell
2
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Sarcoma
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Mesothelioma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Interventions
Rituximab
55
Cyclophosphamide
41
Lenalidomide
25
Vincristine
23
Doxorubicin
22
Prednisone
21
Etoposide
16
ibrutinib
12
Gemcitabine
12
fludarabine phosphate
10
fludarabine
10
Peripheral Blood Stem Cell Transplantation
10
Carboplatin
10
Bendamustine Hydrochloride
10
Ifosfamide
9
Filgrastim
8
polatuzumab vedotin
7
obinutuzumab
7
Oxaliplatin
7
Mycophenolic Acid
7
Methotrexate
6
Cyclosporine
6
venetoclax
5
tafasitamab
5
Vorinostat
5
Radiotherapy
5
R-CHOP protocol
5
Prednisolone
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Large B-Cell, Diffuse
×
tremelimumab
×
Clear all
NCT02205333
2017-06-28
MEDI6469
MedImmune LLC
Phase 1/2
Terminated
48 enrolled
28 charts